Allylescaline

4-Allyloxy-3,5-dimethoxyphenethylamine

AL, Allylmescaline

Psychoactive Class

Chemical Class

Allylescaline is a psychedelic substance in the phenethylamine and scaline classes, and is structurally related to mescaline and escaline. Otakar Leminger reported the compound in 1972,¹ and Alexander Shulgin later discussed it in his 1991 book PiHKAL.² It appeared as a novel designer drug in 2013.³ Allylescaline remains relatively uncommon, with little documented history of human use.

Dosage & Duration

Dosage

Threshold~15 mg

Light20-30 mg

Moderate30-40 mg

Strong40-60 mg

Heavy60+ mg

Duration

Onset45-240 minutes

Peak1-1.25 hours

After Effects1-16 hours

Total8-12 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Forked from Subjective Effect Documentation work

by Josie KinsAugust 2016.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Allylescaline acts on the serotonin 5-HT2 receptor family, including 5-HT2A, 5-HT2B, and 5-HT2C⁴, with its psychedelic activity believed to stem primarily from its efficacy at 5-HT2A. It has been described both as a partial agonist and as a potent agonist at these receptors. Allylescaline also displays weak interactions with dopamine D2-like receptors.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Tolerance

Full Tolerance

Develops almost immediately after ingestion.

Baseline Reset

7 days

Half Tolerance

Approximately 3 days

Cross Tolerance

Psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Allylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Physical

Extremely Low

No evidence of physical dependence. The substance is described as not habit-forming.

History & Culture

Allylescaline was first documented in the scientific literature by Czech chemist Otakar Leminger in 1972.¹ The compound received broader attention when American chemist Alexander Shulgin synthesized and characterized its psychoactive effects, publishing his findings…

Trip Reports

Legality

By Country

United StatesUnscheduled

Not directly scheduled under the Controlled Substances Act. However, due to structural similarities with mescaline, sale for human consumption or use for illicit purposes could potentially be prosecuted under the Federal Analogue Act.

JapanControlled substance

Designated as a controlled substance effective March 25, 2015.

SwitzerlandControlled (Verzeichnis E)

Specifically named and controlled under Verzeichnis E of Swiss narcotics legislation.

GermanyAnlage I BtMG

Controlled under the Narcotics Act (Betäubungsmittelgesetz) Schedule I since February 1, 1997, listed as '4-Allyloxy-3,5-dimethoxy-phenethylazan'. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensation without a license are prohibited.

SwedenIllegal

Classified as an illegal substance since January 2016.⁵

United KingdomIllegal (Psychoactive Substances Act)

Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016.⁶

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Allylescaline article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Allylescaline

4-Allyloxy-3,5-dimethoxyphenethylamine

AL, Allylmescaline

Psychoactive Class

Psychedelic Hallucinogen

Chemical Class

Scaline Phenethylamine (substituted)